JP2018517734A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018517734A5 JP2018517734A5 JP2017565048A JP2017565048A JP2018517734A5 JP 2018517734 A5 JP2018517734 A5 JP 2018517734A5 JP 2017565048 A JP2017565048 A JP 2017565048A JP 2017565048 A JP2017565048 A JP 2017565048A JP 2018517734 A5 JP2018517734 A5 JP 2018517734A5
- Authority
- JP
- Japan
- Prior art keywords
- dfx
- pharmaceutical composition
- poly
- composition
- pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960001489 deferasirox Drugs 0.000 claims description 309
- FMSOAWSKCWYLBB-VBGLAJCLSA-N deferasirox Chemical compound C1=CC(C(=O)O)=CC=C1N(N\C(N\1)=C\2C(C=CC=C/2)=O)C/1=C\1C(=O)C=CC=C/1 FMSOAWSKCWYLBB-VBGLAJCLSA-N 0.000 claims description 309
- 239000008194 pharmaceutical composition Substances 0.000 claims description 218
- 238000000034 method Methods 0.000 claims description 95
- 229920001577 copolymer Polymers 0.000 claims description 93
- 239000000203 mixture Substances 0.000 claims description 84
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 81
- 229920003168 pharmaceutical polymer Polymers 0.000 claims description 60
- 229920000193 polymethacrylate Polymers 0.000 claims description 50
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 46
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 40
- 239000011118 polyvinyl acetate Substances 0.000 claims description 40
- 229920001223 polyethylene glycol Polymers 0.000 claims description 39
- 239000002202 Polyethylene glycol Substances 0.000 claims description 33
- 239000006185 dispersion Substances 0.000 claims description 32
- IWVKTOUOPHGZRX-UHFFFAOYSA-M methyl 2-methylprop-2-enoate;2-methylprop-2-enoate Chemical compound CC(=C)C([O-])=O.COC(=O)C(C)=C IWVKTOUOPHGZRX-UHFFFAOYSA-M 0.000 claims description 32
- 239000002131 composite material Substances 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- -1 acetate-polyethylene Chemical group 0.000 claims description 24
- 239000006186 oral dosage form Substances 0.000 claims description 24
- 239000003795 chemical substances by application Substances 0.000 claims description 23
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 22
- 238000013329 compounding Methods 0.000 claims description 19
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 claims description 18
- 229920000578 graft copolymer Polymers 0.000 claims description 18
- 208000014951 hematologic disease Diseases 0.000 claims description 18
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 18
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 18
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 18
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 18
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims description 18
- 208000019838 Blood disease Diseases 0.000 claims description 16
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 16
- SXFILQHETIJGQZ-UHFFFAOYSA-N but-3-enoic acid;phthalic acid Chemical compound OC(=O)CC=C.OC(=O)C1=CC=CC=C1C(O)=O SXFILQHETIJGQZ-UHFFFAOYSA-N 0.000 claims description 16
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 16
- 230000009477 glass transition Effects 0.000 claims description 16
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 16
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 16
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 16
- 229920002554 vinyl polymer Polymers 0.000 claims description 16
- 239000004698 Polyethylene Substances 0.000 claims description 14
- 239000007857 degradation product Substances 0.000 claims description 14
- 235000011187 glycerol Nutrition 0.000 claims description 14
- 229920000573 polyethylene Polymers 0.000 claims description 14
- 239000004094 surface-active agent Substances 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 14
- 239000012062 aqueous buffer Substances 0.000 claims description 12
- 239000002552 dosage form Substances 0.000 claims description 12
- 239000000194 fatty acid Substances 0.000 claims description 12
- 230000009246 food effect Effects 0.000 claims description 12
- 235000021471 food effect Nutrition 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 11
- 238000002441 X-ray diffraction Methods 0.000 claims description 10
- 238000003860 storage Methods 0.000 claims description 10
- 239000001856 Ethyl cellulose Substances 0.000 claims description 8
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 8
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 8
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 8
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 8
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 8
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 8
- 230000015556 catabolic process Effects 0.000 claims description 8
- 238000006731 degradation reaction Methods 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 229920001249 ethyl cellulose Polymers 0.000 claims description 8
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 8
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 8
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 8
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 8
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 7
- 235000009200 high fat diet Nutrition 0.000 claims description 7
- 229920003067 (meth)acrylic acid ester copolymer Polymers 0.000 claims description 6
- AVPDLWTUGIZJLH-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C([O-])=O.C[NH+](C)CCOC(=O)C(C)=C AVPDLWTUGIZJLH-UHFFFAOYSA-N 0.000 claims description 6
- CDOUZKKFHVEKRI-UHFFFAOYSA-N 3-bromo-n-[(prop-2-enoylamino)methyl]propanamide Chemical compound BrCCC(=O)NCNC(=O)C=C CDOUZKKFHVEKRI-UHFFFAOYSA-N 0.000 claims description 6
- 206010065973 Iron Overload Diseases 0.000 claims description 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 6
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 claims description 6
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 6
- 208000007502 anemia Diseases 0.000 claims description 6
- 208000005980 beta thalassemia Diseases 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 6
- 229920002301 cellulose acetate Polymers 0.000 claims description 6
- 229920006217 cellulose acetate butyrate Polymers 0.000 claims description 6
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 claims description 6
- 238000007922 dissolution test Methods 0.000 claims description 6
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 6
- 229920000151 polyglycol Polymers 0.000 claims description 6
- 239000010695 polyglycol Substances 0.000 claims description 6
- 229920000642 polymer Polymers 0.000 claims description 6
- 230000004044 response Effects 0.000 claims description 6
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 6
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 6
- 229950006451 sorbitan laurate Drugs 0.000 claims description 6
- 235000011067 sorbitan monolaureate Nutrition 0.000 claims description 6
- 238000013268 sustained release Methods 0.000 claims description 6
- 239000012730 sustained-release form Substances 0.000 claims description 6
- 208000018706 hematopoietic system disease Diseases 0.000 claims description 5
- 239000013543 active substance Substances 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 239000008188 pellet Substances 0.000 claims description 4
- 239000004014 plasticizer Substances 0.000 claims description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 4
- 229920000053 polysorbate 80 Polymers 0.000 claims description 4
- 229920003169 water-soluble polymer Polymers 0.000 claims description 4
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 2
- RFRMMZAKBNXNHE-UHFFFAOYSA-N 6-[4,6-dihydroxy-5-(2-hydroxyethoxy)-2-(hydroxymethyl)oxan-3-yl]oxy-2-(hydroxymethyl)-5-(2-hydroxypropoxy)oxane-3,4-diol Chemical compound CC(O)COC1C(O)C(O)C(CO)OC1OC1C(O)C(OCCO)C(O)OC1CO RFRMMZAKBNXNHE-UHFFFAOYSA-N 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 2
- 102000003951 Erythropoietin Human genes 0.000 claims description 2
- 108090000394 Erythropoietin Proteins 0.000 claims description 2
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 claims description 2
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 claims description 2
- TZXKOCQBRNJULO-UHFFFAOYSA-N Ferriprox Chemical compound CC1=C(O)C(=O)C=CN1C TZXKOCQBRNJULO-UHFFFAOYSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 claims description 2
- 208000001132 Osteoporosis Diseases 0.000 claims description 2
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- 208000002903 Thalassemia Diseases 0.000 claims description 2
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims description 2
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims description 2
- 229960003942 amphotericin b Drugs 0.000 claims description 2
- 229940121375 antifungal agent Drugs 0.000 claims description 2
- 239000003429 antifungal agent Substances 0.000 claims description 2
- 229960001631 carbomer Drugs 0.000 claims description 2
- OEUUFNIKLCFNLN-LLVKDONJSA-N chembl432481 Chemical compound OC(=O)[C@@]1(C)CSC(C=2C(=CC(O)=CC=2)O)=N1 OEUUFNIKLCFNLN-LLVKDONJSA-N 0.000 claims description 2
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 2
- 229960000913 crospovidone Drugs 0.000 claims description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000013078 crystal Substances 0.000 claims description 2
- 229960003266 deferiprone Drugs 0.000 claims description 2
- 229960000958 deferoxamine Drugs 0.000 claims description 2
- 230000001419 dependent effect Effects 0.000 claims description 2
- 210000003743 erythrocyte Anatomy 0.000 claims description 2
- 229940105423 erythropoietin Drugs 0.000 claims description 2
- 150000002314 glycerols Chemical class 0.000 claims description 2
- 239000002114 nanocomposite Substances 0.000 claims description 2
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 229940089617 risedronate Drugs 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 230000003628 erosive effect Effects 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562180998P | 2015-06-17 | 2015-06-17 | |
| US62/180,998 | 2015-06-17 | ||
| PCT/US2016/038089 WO2016205658A1 (en) | 2015-06-17 | 2016-06-17 | Improved formulations of deferasirox and methods of making the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018517734A JP2018517734A (ja) | 2018-07-05 |
| JP2018517734A5 true JP2018517734A5 (https=) | 2019-05-30 |
Family
ID=57546755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017565048A Pending JP2018517734A (ja) | 2015-06-17 | 2016-06-17 | デフェラシロクスの改善された製剤およびその作製方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US10265301B2 (https=) |
| EP (1) | EP3310354B1 (https=) |
| JP (1) | JP2018517734A (https=) |
| CN (1) | CN107847490A (https=) |
| AU (3) | AU2016280280B2 (https=) |
| CA (1) | CA2989145C (https=) |
| HK (1) | HK1254608A1 (https=) |
| IL (1) | IL256322B (https=) |
| MA (1) | MA43271A (https=) |
| WO (1) | WO2016205658A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103290106B (zh) | 2007-12-05 | 2015-07-29 | 考利达基因组股份有限公司 | 测序反应中碱基的有效确定 |
| US10098857B2 (en) | 2008-10-10 | 2018-10-16 | The Board Of Trustees Of The Leland Stanford Junior University | Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds |
| DK2443236T3 (en) | 2009-06-15 | 2015-08-17 | Complete Genomics Inc | Methods and compositions for sequencing by long fragment reading |
| US10837879B2 (en) | 2011-11-02 | 2020-11-17 | Complete Genomics, Inc. | Treatment for stabilizing nucleic acid arrays |
| CZ2017255A3 (cs) * | 2017-05-04 | 2018-11-14 | Zentiva, K.S. | Filmem potažené tablety Deferasiroxu |
| US11331288B2 (en) | 2017-09-14 | 2022-05-17 | The Board Of Trustees Of The Leland Stanford Junior University | Conditioning irradiated tissue for increasing vascularity |
| CN111511365A (zh) * | 2017-11-10 | 2020-08-07 | 分散技术有限责任公司 | 改进的药物制剂 |
| US20210315789A1 (en) * | 2018-09-20 | 2021-10-14 | Tautona Group Ip Holding Company, L.L.C. | Iron chelators for treating aesthetic skin conditions |
| CA3168680A1 (en) | 2020-01-31 | 2021-08-05 | Nanocopoeia, Llc | Amorphous nilotinib microparticles and uses thereof |
| WO2021222739A1 (en) | 2020-04-30 | 2021-11-04 | Nanocopoeia, Llc | Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib |
| CN112870361A (zh) * | 2021-01-28 | 2021-06-01 | 重庆医科大学 | 铁死亡抑制剂在制备预防或治疗铁过载导致的骨质疏松或骨丢失的药物中的应用 |
| CN116203161A (zh) * | 2022-05-30 | 2023-06-02 | 上海奥科达医药科技股份有限公司 | 地拉罗司颗粒剂中相关杂质的检测方法 |
| WO2025151876A1 (en) * | 2024-01-11 | 2025-07-17 | Minneamrita Therapeutics Llc | Triptolide formulations |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0009056D0 (en) * | 2000-04-12 | 2000-05-31 | Nestle Sa | Composition comprising free amino acids |
| EP1940360A1 (en) * | 2005-10-19 | 2008-07-09 | Novartis AG | Dispersible tablets comprising deferasirox |
| CA3076115C (en) | 2007-08-21 | 2022-06-28 | Board Of Regents, The University Of Texas System | Thermo-kinetic mixing for pharmaceutical applications |
| EP2062572A1 (en) * | 2007-11-19 | 2009-05-27 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical compositions |
| US20110097413A1 (en) * | 2008-04-21 | 2011-04-28 | Actavis Group Ptc Ehf | Solid state forms of deferasirox salts and process for the preparation thereof |
| WO2011070560A1 (en) | 2009-12-07 | 2011-06-16 | Mapi Pharma Hk Limited | Processes for the preparation of deferasirox, and deferasirox polymorphs |
| US8703203B2 (en) | 2010-07-08 | 2014-04-22 | Ratiopharm Gmbh | Oral dosage form of deferasirox |
| WO2012025935A2 (en) * | 2010-08-25 | 2012-03-01 | Ramamohan Rao Davuluri | A process for the preparation of 2-(2-hydroxyphenyl)-benz[1,3]oxazin-4-one and its use for preparation of 4-[3, 5-bis (2-hydroxyphenyl)-1h-1, 2, 4-triazol-1-yl] benzoic acid |
| MY165826A (en) | 2010-10-01 | 2018-05-17 | Cipla Ltd | Pharmaceutical composition |
| US20140039031A1 (en) * | 2011-02-23 | 2014-02-06 | Dispersol Technologies. LLC | Pharmaceutical formulations of acetyl-11-keto-b-boswellic acid, diindolylmethane, and curcumin for pharmaceutical applications |
| ME03297B (me) | 2013-03-08 | 2019-07-20 | Novartis Ag | Oralne formulacije deferasiroksa |
| HK1215191A1 (zh) * | 2013-05-10 | 2016-08-19 | Cipla Limited | 低剂量医药组合物 |
-
2016
- 2016-06-17 CN CN201680042313.0A patent/CN107847490A/zh active Pending
- 2016-06-17 AU AU2016280280A patent/AU2016280280B2/en active Active
- 2016-06-17 WO PCT/US2016/038089 patent/WO2016205658A1/en not_active Ceased
- 2016-06-17 US US15/185,888 patent/US10265301B2/en active Active
- 2016-06-17 HK HK18113574.7A patent/HK1254608A1/zh unknown
- 2016-06-17 MA MA043271A patent/MA43271A/fr unknown
- 2016-06-17 EP EP16812529.2A patent/EP3310354B1/en active Active
- 2016-06-17 JP JP2017565048A patent/JP2018517734A/ja active Pending
- 2016-06-17 CA CA2989145A patent/CA2989145C/en active Active
-
2017
- 2017-06-28 US US15/636,174 patent/US10258608B2/en active Active
- 2017-12-14 IL IL256322A patent/IL256322B/en unknown
-
2019
- 2019-02-06 US US16/268,785 patent/US11878005B2/en active Active
-
2021
- 2021-12-02 AU AU2021277731A patent/AU2021277731B2/en active Active
-
2023
- 2023-11-24 US US18/518,819 patent/US20240091201A1/en active Pending
-
2024
- 2024-04-17 AU AU2024202528A patent/AU2024202528B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018517734A5 (https=) | ||
| US12403140B2 (en) | Pharmaceutical compositions of nilotinib | |
| EP2566462B1 (en) | Immediate release formulations and dosage forms of gamma-hydroxybutyrate | |
| TWI649098B (zh) | （ｓ）-（１-（（４-（３-（５-氯-２-氟-３-（甲基磺醯胺基）苯基-１-異丙基-１ｈ-吡唑-４-基）嘧啶-２-基）胺基）丙-２-基)胺基甲酸甲酯之固體醫藥調配物 | |
| US11590127B2 (en) | Gastro-resistant formulation containing posaconazole | |
| AU2017262586B2 (en) | Improved drug formulations | |
| JP2019514993A5 (https=) | ||
| WO2016020080A1 (en) | Pharmaceutical compositions of edoxaban | |
| EP3389633A1 (en) | Pharmaceutical compositions comprising phenylaminopyrimidine derivative | |
| WO2008029417A2 (en) | Pharmaceutical formulation for use in hiv therapy | |
| EP1793801A1 (en) | Novel granulation process and granulate produced therefrom | |
| WO2016020305A1 (en) | Aqueous granulation process for amorphous poorly water soluble drugs | |
| KR101233235B1 (ko) | 초기 용출율이 개선된 프란루카스트 고체분산체의 약제학적조성물 및 그의 제조방법 | |
| EP3210599B1 (en) | Gastro-resistant formulation containing posaconazole and a polymeric precipitation inhibitor | |
| JP7378393B2 (ja) | 改善された薬物製剤 | |
| JP2017119632A (ja) | 経口固形組成物 | |
| US20190125678A1 (en) | Sustained-Release Oral Dosage Forms for Low Aqueous Solubility Compounds | |
| EP3731812B1 (en) | Water-dispersible tablet formulations comprising deferasirox | |
| KR100581169B1 (ko) | 용해도가 개선된 테르비나핀의 약제조성물 및 그 제조방법 | |
| CN104324014A (zh) | 一种含醋酸卡泊芬净的药物组合物缓释植入剂及其制备 | |
| TR2021004272A2 (tr) | Deferasi̇roks i̇çeren fi̇lm kapli tablet | |
| EP2846778B1 (en) | Oral solid dosage formulation of 1,1-dimethylethyl [(1s)-1-{[(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate | |
| AU2018214291A1 (en) | Composition comprising immediate release and extended release Capecitabine | |
| HK1182964A (en) | Immediate release formulations and dosage forms of gamma-hydroxybutyrate | |
| HK1182964B (en) | Immediate release formulations and dosage forms of gamma-hydroxybutyrate |